Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 8/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 7/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CASP1 | P29466 | 2/20 | 0.35 |
| ▸ | CD44 | P16070 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27522944 | 0.84 | CYP3A4 (0.55) | CYP3A4TP53ALDH1A1GAATHRB | |
| SCHEMBL1041423 | 0.80 | CYP3A4 (0.39) | CYP3A4TP53ALDH1A1GAATHRB | |
| SCHEMBL5528095 | 0.80 | CASP1 (0.44) | CYP3A4TP53ALDH1A1GAATHRB | |
| SCHEMBL3650638 | 0.79 | CYP3A4 (0.54) | CYP3A4TP53ALDH1A1GAATHRB | |
| SCHEMBL1040870 | 0.74 | TSHR (0.45) | CYP3A4TP53ALDH1A1GAATHRB | |
| SCHEMBL11398114 | 0.74 | KDM4E (0.40) | CYP3A4TP53ALDH1A1GAATHRB | |
| SCHEMBL3303530 | 0.73 | ALDH1A1 (0.47) | CYP3A4TP53ALDH1A1GAATHRB | |
| SCHEMBL1462101 | 0.73 | GAA (0.40) | CYP3A4TP53ALDH1A1GAAPTK2 | |
| SCHEMBL7190503 | 0.72 | CYP3A4 (0.70) | CYP3A4TP53ALDH1A1GAATHRB | |
| SCHEMBL31396152 | 0.72 | CYP3A4 (0.70) | CYP3A4TP53ALDH1A1GAATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1263324-B1 | RADIOGRAPHIC ASSESSMENT OF TISSUE RESPONSE TO COMPOUNDS | VERITAS PHARMACEUTICALS (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20040170561-A1 | Functional radiographic imaging methods and agents | SALB JESSE (US) | 2004-09-02 | — | — | US | disclosed |
| US-6751290-B2 | Radiographic assessment of tissue after exposure to a compound | VERITAS PHARMACEUTICALS, INC. | 2004-06-15 | — | — | US | disclosed |
| US-6723746-B2 | CELL MEMBRANE-PERMEABLE, RADIO-OPAQUE IMAGING AGENT | VERITAS PHARMACEUTICALS, INC. | 2004-04-20 | — | — | US | disclosed |
| EP-1263478-A2 | FUNCTIONAL RADIOGRAPHIC IMAGING METHODS AND AGENTS | Veritas Pharmaceuticals (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020039401-A1 | Radiographic assessment of tissue after exposure to a compound | VERITAS PHARMACEUTICALS, INC. | 2002-04-04 | — | — | US | disclosed |
| US-20010038682-A1 | Radiographic assessment of tissue response to compounds | VERITAS PHARMACEUTICALS INC., A DELAWARE CORP. | 2001-11-08 | — | — | US | disclosed |
| US-20010031035-A1 | Functional radiographic imaging methods and agents | VERITAS PHARMACEUTICALS INC. | 2001-10-18 | — | — | US | disclosed |
| WO-2001068151-A2 | FUNCTIONAL RADIOGRAPHIC IMAGING METHODS AND AGENTS | VERITAS PHARMACEUTICALS (US) | 2001-09-20 | — | — | WO | disclosed |
| US-4296260-A | Process for the preparation of phloroglucinol | AKZONA INCORPORATED (US) | 1981-10-20 | — | — | US | disclosed |
| US-4157450-A | Benzene-1,3,5-tris-acetoxime and the process for making phloroglucinol therewith | AKZONA INCORPORATED (US) | 1979-06-05 | — | — | US | disclosed |
| US-4123461-A | Benzene-tricarboxylic acid-(1,3,5)-tri-N-chloramide and process for the preparation thereof | AKZONA INCORPORATED (US) | 1978-10-31 | — | — | US | disclosed |
| US-4115451-A | Benzene-1,3,5-tris-acetoxime and the process for making phloroglucinol therewith | AKZONA INCORPORATED (US) | 1978-09-19 | — | — | US | disclosed |
| US-4071555-A | Benzene-1,3,5-tris-acetoxime and the process for making phloroglucinol therewith | AKZONA INCORPORATED (US) | 1978-01-31 | — | — | US | disclosed |
| US-4057588-A | Process for the preparation of phloroglucinol | AKZONA INCORPORATED (US) | 1977-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040170561-A1 | Functional radiographic imaging methods and agents | GPR180, TMEM120A, RXFP1 | CYP3A4 4792/4885TP53 637/4885ALDH1A1 4200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.